July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Phase 2 Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2
Author Affiliations & Notes
  • Emily Y. Chew
    Epidemiology & Clinical Applications, National Eye Inst/NIH, Bethesda, Maryland, United States
  • Traci E Clemons
    The Emmes Corporation, Rockville, Maine, United States
  • Glenn J Jaffe
    Duke University, Durham, North Carolina, United States
  • Sina Farsiu
    Duke University, Durham, North Carolina, United States
  • eleonora lad
    Duke University, Durham, North Carolina, United States
  • Martin Friedlander
    Scripps Research Institute, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Emily Chew, None; Traci Clemons, None; Glenn Jaffe, Heidelberg Engineering (C); Sina Farsiu, Duke University (P); eleonora lad, Apellis (C), Apellis (R), Jansen (C), Roche (C), Roche (R), Stealth (C); Martin Friedlander, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2605. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emily Y. Chew, Traci E Clemons, Glenn J Jaffe, Sina Farsiu, eleonora lad, Martin Friedlander; Phase 2 Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2605.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Macular telangiectasia type 2 (MacTel), a bilateral neurodegenerative retinal disease that leads to marked deficits in near visual function, has no proven effective therapy. We tested whether encapsulated cell-based intravitreal sustained delivery of human ciliary neurotrophic
factor (CNTF) in an implant surgically placed in the vitreous provided a benefit for this condition.

Methods : This multi-center, single-masked sham-controlled study in 11 clinical sites in the United States and Australia enrolled participants with Mac Tel type 2. One eye of bilateral eligible participants received the implant of CNTF while the fellow eye had sham treatment. Pariticpants with unilaterl eligible eye were randomized to treatment or sham. The primary outcome was the difference in the area of neurodegeneration or the ellipzoid zone (EZ) loss at 24 months from baseline. Functional changes include microperimetry, and reading speed.

Results : The study population of 67 participants (99 eyes) was mostly white, 61% were women, and the median age was 62 years (range 44-79 years). The mean best corrected visual acuity at baseline of 20/30. Two deaths occurred during the study. All surviving participants were followed to the final 24-month study visit. Eyes receiving the sham treatment had 31% greater progression of neurodegeneration than the CNTF-treated eyes, the difference in mean area of photoreceptor loss was 0.05 ± 0.03 mm2 (p=0.039) at 24 months. Retinal sensitivity changes, measured using microperimetry, a visual field test, were highly correlated with the changes in the area of photoreceptor loss (r = 0.86, p <0.0001). The mean retinal sensitivity loss of the sham group was 45% greater than the treated. As expected, there was no change in visual acuity between the treatment groups. However, there was a stabilization of the reading speed in the treated eyes while the sham eyes continued to experience reduced reading speed (p=0.016) at month 24 compared with baseline.

Conclusions : CNTF treatment delivered by NT501 was safe and well tolerated. CNTF had a beneficial effect and reduced the progressive loss of photoreceptors compared to untreated eyes. This is the first clinical trial to demonstrate that a neuroprotective agent that has
the potential to slow progressive retinal neurodegeneration in MacTel. These results are sufficiently encouraging to support future phase 3 studies in Mac Tel type 2.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×